Creo Medical Group (LSE:CREO) delivered a strong performance in FY25, with revenue increasing by 50% to £6.0 million alongside a sharp improvement in cost efficiency. Underlying operating expenses fell 20% to £18.4 million, helping to cut the underlying operating loss by more than 40% to £13.3 million. The group ended the year with a cash balance of £12.4 million.
Revenue growth was driven by continued clinical adoption and higher utilisation across Creo’s core product portfolio. Use of the Speedboat Notch device increased in advanced gastrointestinal procedures, while the newly launched SpydrBlade Flex received encouraging early feedback following its introduction in the US, UK and EU. Progress was also made within the MicroBlate ablation portfolio, supported by commercial sales and limited market releases linked to ongoing clinical studies. Management highlighted confidence in further sequential revenue growth and improving operational leverage in FY26, positioning the business towards more sustainable cash flows as scale builds.
Looking ahead, Creo Medical’s outlook reflects a mix of improving operational momentum and ongoing financial challenges. While the company remains loss-making and valuation metrics continue to reflect this, recent progress in cost control, product adoption and commercial execution provides a more constructive backdrop for future growth in the minimally invasive endoscopic oncology market.
More about Creo Medical
Creo Medical Group is a UK-based medical device company focused on minimally invasive electrosurgical technologies for use in endoscopic procedures for pre-cancer and cancer patients. Its proprietary CROMA platform, powered by Kamaptive technology, combines bipolar radiofrequency and microwave energy to enable tissue resection, dissection, coagulation and ablation. The group aims to provide clinicians with safer, more precise and cost-effective alternatives to conventional surgical techniques, particularly in gastrointestinal and related applications.
Leave a Reply